Beth Hecht - Net Worth and Insider Trading

Beth Hecht Net Worth

The estimated net worth of Beth Hecht is at least $110,170 dollars as of 2024-05-26. Beth Hecht is the See Remarks of Xeris Biopharma Holdings Inc and owns about 57,083 shares of Xeris Biopharma Holdings Inc (XERS) stock worth over $110,170. Details can be seen in Beth Hecht's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Beth Hecht has not made any transactions after 2020-03-13 and currently still holds the listed stock(s).

Transaction Summary of Beth Hecht

To

Beth Hecht Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Beth Hecht owns 4 companies in total, including Xeris Biopharma Holdings Inc (XERS) , Neos Therapeutics Inc (NEOS) , and Aytu BioPharma Inc (AYTU) among others .

Click here to see the complete history of Beth Hecht’s form 4 insider trades.

Insider Ownership Summary of Beth Hecht

Ticker Comapny Transaction Date Type of Owner
XERS Xeris Biopharma Holdings Inc 2021-10-05 See Remarks
NEOS Neos Therapeutics Inc 2020-06-10 director
AYTU Aytu BioPharma Inc 2021-03-19 director
2021-03-18 director

Beth Hecht Latest Holdings Summary

Beth Hecht currently owns a total of 1 stock. Beth Hecht owns 57,083 shares of Xeris Biopharma Holdings Inc (XERS) as of March 13, 2020, with a value of $110,170.

Latest Holdings of Beth Hecht

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
XERS Xeris Biopharma Holdings Inc 2020-03-13 57,083 1.93 110,170

Holding Weightings of Beth Hecht


Beth Hecht Form 4 Trading Tracker

According to the SEC Form 4 filings, Beth Hecht has made a total of 2 transactions in Xeris Biopharma Holdings Inc (XERS) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Xeris Biopharma Holdings Inc is the acquisition of 4,000 shares on March 13, 2020, which cost Beth Hecht around $7,880.

Insider Trading History of Beth Hecht

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Beth Hecht Trading Performance

GuruFocus tracks the stock performance after each of Beth Hecht's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Beth Hecht is 36.91%. GuruFocus also compares Beth Hecht's trading performance to market benchmark return within the same time period. The performance of stocks bought by Beth Hecht within 3 months outperforms 3 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Beth Hecht's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Beth Hecht

Average Return

Average return per transaction

Outperforming Transactions

2 out of 3 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -19.39
Relative Return to S&P 500(%) -14.04

Beth Hecht Ownership Network

Ownership Network List of Beth Hecht

No Data

Ownership Network Relation of Beth Hecht


Beth Hecht Owned Company Details

What does Xeris Biopharma Holdings Inc do?

Who are the key executives at Xeris Biopharma Holdings Inc?

Beth Hecht is the See Remarks of Xeris Biopharma Holdings Inc. Other key executives at Xeris Biopharma Holdings Inc include Chief Financial Officer Steven Pieper , See Remarks Shannon John Patrick Jr , and director & See Remarks Paul R Edick .

Xeris Biopharma Holdings Inc (XERS) Insider Trades Summary

Over the past 18 months, Beth Hecht made no insider transaction in Xeris Biopharma Holdings Inc (XERS). Other recent insider transactions involving Xeris Biopharma Holdings Inc (XERS) include a net purchase of 16,400 shares made by John P. Schmid , a net purchase of 30,000 shares made by Paul R Edick , and a net purchase of 30,769 shares made by Shannon John Patrick Jr .

In summary, during the past 3 months, insiders sold 0 shares of Xeris Biopharma Holdings Inc (XERS) in total and bought 9,900 shares, with a net purchase of 9,900 shares. During the past 18 months, 0 shares of Xeris Biopharma Holdings Inc (XERS) were sold and 115,979 shares were bought by its insiders, resulting in a net purchase of 115,979 shares.

Xeris Biopharma Holdings Inc (XERS)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Xeris Biopharma Holdings Inc Insider Transactions

No Available Data

Beth Hecht Mailing Address

Above is the net worth, insider trading, and ownership report for Beth Hecht. You might contact Beth Hecht via mailing address: C/o Neos Therapeutics, Inc., 2940 N. Highway 360, Grand Prairie Tx 75050.

Discussions on Beth Hecht

No discussions yet.